🇺🇸 Bortezomib (Velcade®) in United States

30 US adverse-event reports

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

• Window: 20 April 2025 – 20 April 2026
• Total reports: 30

Most-reported reactions

1. Dyspnoea — 5 reports (16.67%)
2. Dysphagia — 3 reports (10%)
3. Fatigue — 3 reports (10%)
4. Haemoglobin Decreased — 3 reports (10%)
5. Headache — 3 reports (10%)
6. Heart Rate Irregular — 3 reports (10%)
7. Neutropenia — 3 reports (10%)
8. Pleural Effusion — 3 reports (10%)
9. Anaemia — 2 reports (6.67%)
10. Feeling Cold — 2 reports (6.67%)

Source database →

Frequently asked questions

Is Bortezomib (Velcade®) approved in United States?

Bortezomib (Velcade®) does not currently have US marketing authorisation in our dataset.

Who is the marketing authorisation holder for Bortezomib (Velcade®) in United States?

Pfizer Inc. is the originator. The local marketing authorisation holder may differ — check the official source linked above.